FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048460059> ?p ?o ?g. }

• W2048460059 endingPage "2144" @default.
• W2048460059 startingPage "2137" @default.
• W2048460059 abstract "Abstract Purpose: ATN-161 (Ac-PHSCN-NH2) is an integrin-binding peptide that is currently in phase II trials in cancer patients. This peptide has been shown to have antitumor activity in a number of different preclinical models. Experimental Design: In this study, we examined the binding, biodistribution, and dose and biomarker response of ATN-161 in several animal models. Results: ATN-161 bound to the β subunit of a number of different integrins implicated in tumor growth and progression, which depended on its cysteine thiol. The peptide had antiangiogenic activity in the Matrigel plug model, and this activity could be reversed by inhibitors of protein kinase A, an effector of α5β1-dependent angiogenesis. A labeled analogue of ATN-161, ATN-453, localized to neovessels but not to preexisting vasculature in vivo. The half-life of the peptide when localized to a tumor was much longer than in plasma. Dose-response studies in the Matrigel plug model of angiogenesis or a Lewis lung carcinoma model of tumor growth showed a U-shaped dose-response curve with 1 to 10 mg/kg given thrice a week, being the optimal dose range of ATN-161. Two additional pharmacodynamic models of angiogenesis (dynamic contrast-enhanced magnetic resonance imaging and measurement of endothelial cell progenitors) also revealed U-shaped dose-response curves. Conclusions: The presence of a U-shaped dose-response curve presents a significant challenge to identifying a biologically active dose of ATN-161. However, the identification of biomarkers of angiogenesis that also exhibit this same U-shaped response should allow the translation of those biomarkers to the clinic, allowing them to be used to identify the active dose of ATN-161 in phase II studies." @default.
• W2048460059 created "2016-06-24" @default.
• W2048460059 creator A5010799165 @default.
• W2048460059 creator A5014366720 @default.
• W2048460059 creator A5021263152 @default.
• W2048460059 creator A5028466230 @default.
• W2048460059 creator A5052245382 @default.
• W2048460059 creator A5057495399 @default.
• W2048460059 creator A5065530824 @default.
• W2048460059 creator A5068166516 @default.
• W2048460059 creator A5070032076 @default.
• W2048460059 creator A5074305095 @default.
• W2048460059 creator A5079847418 @default.
• W2048460059 creator A5089205392 @default.
• W2048460059 date "2008-04-01" @default.
• W2048460059 modified "2023-10-10" @default.
• W2048460059 title "Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth" @default.
• W2048460059 cites W110134706 @default.
• W2048460059 cites W1968539943 @default.
• W2048460059 cites W1972543827 @default.
• W2048460059 cites W1973835078 @default.
• W2048460059 cites W1988175245 @default.
• W2048460059 cites W1996257032 @default.
• W2048460059 cites W1998033848 @default.
• W2048460059 cites W2000723196 @default.
• W2048460059 cites W2012852444 @default.
• W2048460059 cites W2019097838 @default.
• W2048460059 cites W2035808363 @default.
• W2048460059 cites W2038561272 @default.
• W2048460059 cites W2054119278 @default.
• W2048460059 cites W2063897621 @default.
• W2048460059 cites W2068562114 @default.
• W2048460059 cites W2105190135 @default.
• W2048460059 cites W2106934854 @default.
• W2048460059 cites W2112099873 @default.
• W2048460059 cites W2131279811 @default.
• W2048460059 cites W2131798870 @default.
• W2048460059 cites W2155318909 @default.
• W2048460059 cites W2157752410 @default.
• W2048460059 cites W2163899134 @default.
• W2048460059 cites W2320277402 @default.
• W2048460059 cites W4231258015 @default.
• W2048460059 cites W4240908764 @default.
• W2048460059 cites W4250732702 @default.
• W2048460059 cites W84647915 @default.
• W2048460059 doi "https://doi.org/10.1158/1078-0432.ccr-07-4530" @default.
• W2048460059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18381955" @default.
• W2048460059 hasPublicationYear "2008" @default.
• W2048460059 type Work @default.
• W2048460059 sameAs 2048460059 @default.
• W2048460059 citedByCount "79" @default.
• W2048460059 countsByYear W20484600592012 @default.
• W2048460059 countsByYear W20484600592013 @default.
• W2048460059 countsByYear W20484600592014 @default.
• W2048460059 countsByYear W20484600592015 @default.
• W2048460059 countsByYear W20484600592016 @default.
• W2048460059 countsByYear W20484600592017 @default.
• W2048460059 countsByYear W20484600592018 @default.
• W2048460059 countsByYear W20484600592019 @default.
• W2048460059 countsByYear W20484600592020 @default.
• W2048460059 countsByYear W20484600592021 @default.
• W2048460059 countsByYear W20484600592022 @default.
• W2048460059 countsByYear W20484600592023 @default.
• W2048460059 crossrefType "journal-article" @default.
• W2048460059 hasAuthorship W2048460059A5010799165 @default.
• W2048460059 hasAuthorship W2048460059A5014366720 @default.
• W2048460059 hasAuthorship W2048460059A5021263152 @default.
• W2048460059 hasAuthorship W2048460059A5028466230 @default.
• W2048460059 hasAuthorship W2048460059A5052245382 @default.
• W2048460059 hasAuthorship W2048460059A5057495399 @default.
• W2048460059 hasAuthorship W2048460059A5065530824 @default.
• W2048460059 hasAuthorship W2048460059A5068166516 @default.
• W2048460059 hasAuthorship W2048460059A5070032076 @default.
• W2048460059 hasAuthorship W2048460059A5074305095 @default.
• W2048460059 hasAuthorship W2048460059A5079847418 @default.
• W2048460059 hasAuthorship W2048460059A5089205392 @default.
• W2048460059 hasBestOaLocation W20484600591 @default.
• W2048460059 hasConcept C126322002 @default.
• W2048460059 hasConcept C150903083 @default.
• W2048460059 hasConcept C170493617 @default.
• W2048460059 hasConcept C185592680 @default.
• W2048460059 hasConcept C195687474 @default.
• W2048460059 hasConcept C207001950 @default.
• W2048460059 hasConcept C2778608917 @default.
• W2048460059 hasConcept C2780394083 @default.
• W2048460059 hasConcept C502942594 @default.
• W2048460059 hasConcept C71924100 @default.
• W2048460059 hasConcept C86803240 @default.
• W2048460059 hasConcept C98274493 @default.
• W2048460059 hasConceptScore W2048460059C126322002 @default.
• W2048460059 hasConceptScore W2048460059C150903083 @default.
• W2048460059 hasConceptScore W2048460059C170493617 @default.
• W2048460059 hasConceptScore W2048460059C185592680 @default.
• W2048460059 hasConceptScore W2048460059C195687474 @default.
• W2048460059 hasConceptScore W2048460059C207001950 @default.
• W2048460059 hasConceptScore W2048460059C2778608917 @default.
• W2048460059 hasConceptScore W2048460059C2780394083 @default.
• W2048460059 hasConceptScore W2048460059C502942594 @default.

• next